Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PJPB | ISIN: US45166A1025 | Ticker-Symbol: 30J
Tradegate
22.04.25
08:05 Uhr
15,600 Euro
-1,100
-6,59 %
1-Jahres-Chart
IDEAYA BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
IDEAYA BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
16,60016,70016:21
16,60016,70016:18

Aktuelle News zur IDEAYA BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.04.IDEAYA macht Fortschritte mit Darovasertib in Studie zu Aderhautmelanom1
14.04.IDEAYA advances darovasertib in uveal melanoma trial2
14.04.IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma69Targeting to initiate Phase 3 randomized registrational trial for darovasertib in the neoadjuvant setting in primary UM in H1 2025 Clinical endpoints supportive...
► Artikel lesen
IDEAYA BIOSCIENCES Aktie jetzt für 0€ handeln
10.04.IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer107Initiated Phase 1/2 study expansion for IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy®, Gilead's Trop-2 directed ADC, in MTAP-deletion urothelial...
► Artikel lesen
02.04.IDEAYA Biosciences, Inc. - 8-K, Current Report3
31.03.IDEAYA Biosciences, Inc.: IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma89Designation enables expedited development and priority regulatory review BTD application was supported by updated clinical data from Ph2 neoadjuvant UM trial...
► Artikel lesen
03.03.IDEAYA Biosciences Partners With ATTMOS To Advance AI/ML-Driven Oncology Drug Discovery-
03.03.IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets97SOUTH SAN FRANCISCO, Calif., March 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery...
► Artikel lesen
28.02.IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)-
18.02.IDEAYA Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
18.02.IDEAYA Biosciences, Inc. - 10-K, Annual Report-
13.02.Amgen ends Ideaya cancer combination trial after partner unveils rival molecule19
13.02.IDEAYA Biosciences Q4 Loss Misses Estimates1
13.02.IDEAYA Biosciences GAAP EPS of -$1.49 misses by $0.86, revenue of $0.7M misses by $3.61M2
13.02.IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update139Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled...
► Artikel lesen
13.02.IDEAYA Biosciences, Inc.: IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC200Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy...
► Artikel lesen
10.02.IDEAYA Appoints Joshua Bleharski As CFO-
10.02.IDEAYA Biosciences names Joshua Bleharski as CFO1
10.02.IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer109SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery...
► Artikel lesen
10.02.IDEAYA Biosciences, Inc. - 8-K, Current Report-
Seite:  Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1